Health Canada advises on increased risk of hemolysis with serogroup B meningococcal vaccination

26 October 2016

Medicines regulator Health Canada has issued a warning saying that an increased risk of hemolysis or low hemoglobin has been observed when patients already being treated with Solaris (eculizumab), from Alexion Pharmaceuticals (Nasdaq: ALXN), were vaccinated against serogroup B meningococcal infection with Bexsero, marketed by GlaxoSmithKline (LSE: GSK).

To minimize the risk of hemolysis when patients who are being treated with Solaris are vaccinated, it is recommended that these patients be vaccinated only after their disease has been controlled and within one week following Solaris infusion, when the Solaris concentration in the blood is considered to be relatively high.

It is recommended that:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK